Nothing Special   »   [go: up one dir, main page]

HUP0100352A2 - Compositions derived from mycobacterium vaccae and methods for their use - Google Patents

Compositions derived from mycobacterium vaccae and methods for their use

Info

Publication number
HUP0100352A2
HUP0100352A2 HU0100352A HUP0100352A HUP0100352A2 HU P0100352 A2 HUP0100352 A2 HU P0100352A2 HU 0100352 A HU0100352 A HU 0100352A HU P0100352 A HUP0100352 A HU P0100352A HU P0100352 A2 HUP0100352 A2 HU P0100352A2
Authority
HU
Hungary
Prior art keywords
vaccae
methods
depleted
delipidated
mycobacterium vaccae
Prior art date
Application number
HU0100352A
Other languages
Hungarian (hu)
Inventor
Ross L. Prestidge
Margot A. Skinner
Paul Tan
Elizabeth S. Visser
James Watson
Original Assignee
Genesis Research & Development Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/997,362 external-priority patent/US5985287A/en
Priority claimed from US08/997,080 external-priority patent/US5968524A/en
Priority claimed from US09/095,855 external-priority patent/US6160093A/en
Priority claimed from US09/205,426 external-priority patent/US6406704B1/en
Application filed by Genesis Research & Development Corporation Limited filed Critical Genesis Research & Development Corporation Limited
Publication of HUP0100352A2 publication Critical patent/HUP0100352A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány olyan kompozíciókkal foglalkozik, amelyek jelen vannakMycobacterium vaccae törzsben vagy abból származhatnak, foglalkoziktovábbá eljárásokkal ezeknek a kompozícióknak az alkalmazására olyanrendellenességek kezelésére, megelőzésére és kimutatására, mint afertőző betegségek, immunrendellenességek és rák. A találmány továbbáfoglalkozik eljárással immunválasz fokozására valamely antigénre,amely eljárás magában foglalja M. vaccae tenyészet szűrlet,lipidmentesített M. vaccae sejtek, lipidmentesített és glikolipid-mentesített, mikolsavra kimerített M. vaccae sejtek vagylipidmentesített és glikolipid-mentesített, mikolsavra ésarabinogalaktánra kimerített M. vaccae sejtek beadását. ÓThe invention relates to compositions that are present in or may be derived from Mycobacterium vaccae, and further to methods of using these compositions for the treatment, prevention, and detection of disorders such as infectious diseases, immune disorders, and cancer. The invention also relates to a method for enhancing an immune response to an antigen, which method includes M. vaccae culture filtrate, delipidated M. vaccae cells, delipidated and glycolipid-depleted M. vaccae cells depleted of mycolic acid, or delipidated and glycolipid-depleted M. vaccae cells depleted of mycolic acid and arabinogalactan. administration. HE

HU0100352A 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use HUP0100352A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99662497A 1997-12-23 1997-12-23
US08/997,362 US5985287A (en) 1996-08-29 1997-12-23 Compounds and methods for treatment and diagnosis of mycobacterial infections
US08/997,080 US5968524A (en) 1997-12-23 1997-12-23 Methods and compounds for the treatment of immunologically-mediated psoriasis
US09/095,855 US6160093A (en) 1996-08-29 1998-06-11 Compounds and methods for treatment and diagnosis of mycobacterial infections
US15618198A 1998-09-17 1998-09-17
US09/205,426 US6406704B1 (en) 1996-08-29 1998-12-04 Compounds and methods for treatment and diagnosis of mycobacterial infections
PCT/NZ1998/000189 WO1999032634A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Publications (1)

Publication Number Publication Date
HUP0100352A2 true HUP0100352A2 (en) 2001-06-28

Family

ID=27557521

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100352A HUP0100352A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Country Status (15)

Country Link
EP (1) EP1044273A2 (en)
JP (1) JP2002514385A (en)
CN (1) CN1294632A (en)
AU (1) AU746311B2 (en)
BR (1) BR9814432A (en)
CA (1) CA2315539A1 (en)
HU (1) HUP0100352A2 (en)
ID (1) ID26327A (en)
IL (1) IL136821A0 (en)
MX (1) MXPA00006168A (en)
NO (1) NO20003261L (en)
NZ (1) NZ505834A (en)
PL (1) PL341697A1 (en)
TR (1) TR200001948T2 (en)
WO (1) WO1999032634A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
JP4415200B2 (en) * 1999-01-29 2010-02-17 大塚製薬株式会社 Late-growing mycobacterial polypeptide
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003504079A (en) * 1999-07-12 2003-02-04 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド Compositions for treating infectious diseases and immune system diseases and methods of using the same
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
JP2003508054A (en) * 1999-08-31 2003-03-04 ニーデルバイス，ミヒャエル Method for producing channel-forming protein
EP2336331A1 (en) * 1999-08-31 2011-06-22 Novozymes A/S Novel proteases and variants thereof
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturation-promoting agent for immature dendritic cells
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US20030104012A1 (en) * 2001-05-11 2003-06-05 Corixa Corporation Vaccines for the treatment of autoimmune disease
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CN106103471B (en) * 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 Fusion of heterooligomeric mycobacterial antigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Also Published As

Publication number Publication date
WO1999032634A3 (en) 1999-12-02
NO20003261D0 (en) 2000-06-22
ID26327A (en) 2000-12-14
IL136821A0 (en) 2001-06-14
NO20003261L (en) 2000-08-22
CA2315539A1 (en) 1999-07-01
MXPA00006168A (en) 2005-02-24
WO1999032634A2 (en) 1999-07-01
JP2002514385A (en) 2002-05-21
EP1044273A2 (en) 2000-10-18
NZ505834A (en) 2002-12-20
CN1294632A (en) 2001-05-09
BR9814432A (en) 2000-10-10
PL341697A1 (en) 2001-04-23
TR200001948T2 (en) 2001-02-21
AU746311B2 (en) 2002-04-18
AU1893699A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
HUP0100352A2 (en) Compositions derived from mycobacterium vaccae and methods for their use
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
MXPA01003557A (en) Neisseria genomic sequences and methods of their use.
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
NZ532665A (en) Neisseria meningitidis antigens and compositions
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
DK1185691T3 (en) Genomic neonatal sequences and methods for their use
TR200403064T2 (en) Methods and compounds for the diagnosis and prevention of tuberculosis by immunotherapy.
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
ATE464910T1 (en) HUMAN CD80 MUTANT AND COMPOSITIONS AND METHODS FOR THE PRODUCTION AND USE THEREOF
GB2355983B (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
WO1999059617A3 (en) Immunoregulator
WO2005030136A3 (en) Tumor vaccine
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
DE69839943D1 (en) PREVENT IMMUNOACTIVITY THROUGH INHIBITION OR INHIBITION OF ANTIGEN-PRESENTING CELLS
WO2000027429A3 (en) Vaccine against papillomatous digital dermatitis (pdd)
DE60134408D1 (en) FOR ACCRESSIVE HIV PROTEINS ENCODING DNA VACCINES
WO2004041192A3 (en) Panels of molecular targets differentially expressed during cd8+ t-cell priming
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004003153A3 (en) Live replicating spumavirus vector
WO2001051649A3 (en) Identification of virulence determinants
EP1637166A3 (en) Virus-like particles for the induction of autoantibodies
UA34283A (en) Method for diagnostics of distortions of immunological status in human person and animal